PARP inhibitors have shown efficacy in treating several types of cancers. These include ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer, especially in cases where the tumors harbor BRCA mutations. Ongoing research is evaluating their potential against a broader spectrum of cancers.
